Last updated 2026-09-04
- Went public on NYSE American (RGNT), Dec 2025
- Raised $10M Follow-on PO, Dec 2025
- Raised $15M Series D led by Haisco Pharmaceutical Group, Feb 2016
Total raised
$35.0M
Last: PIPE 2026-06
Stage
Public
Founded
2004
Headcount
8
HQ
Herzliya, Israel
Sector
Health Tech & Life Sciences
About
Regentis Biomaterials is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. The company's current efforts are focused on orthopedic treatments using its Gelrin platform, based on degradable hydrogel implants, to regenerate damaged or diseased tissue, including inflamed cartilage and bone. Its lead product, GelrinC, is a cell-free, off-the-shelf hydrogel implant for the treatment of painful injuries to articular knee cartilage.
Funding history · 3 rounds · $35.0M total
4 events/rounds · $35.0M Total Funding: $25.0M in Private Equity, $20.0M in Public Equity
Dec 2025
Follow-on PO
$10.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Feb 2016
★ Haisco Pharmaceutical GroupT3HaiscoMedica PartnersGenerali InvestmentSCP Vitalife PartnersGenerali Financial HoldingsTechnion Innovation Opportunities FundTechnion Research & Development Foundation
May 2012
★ Royal DSM★ SCPVitalife★ Crossroad Fund★ SCP Vitalife Partners★ Medica Venture Partners★ Technion Investment Opportunities Fund
Headcount over time
8 employees (2026-09) · 1 point
Offices
Herzliya, Israel · HQ / main office
Show all offices (2 more)
- Princeton, United States
- Mnster, Germany
Q&A
- What is Regentis Biomaterials' primary focus?
- Regentis Biomaterials is a regenerative medicine company focused on developing innovative tissue repair solutions, with an initial emphasis on orthopedic treatments using its Gelrin platform.
- When did Regentis Biomaterials go public?
- Regentis Biomaterials went public on NASDAQ in September 2025.
- What is GelrinC?
- GelrinC is Regentis Biomaterials' lead product, a cell-free, off-the-shelf hydrogel implant designed for the treatment of painful injuries to articular knee cartilage.
- What was the amount raised in Regentis Biomaterials' D Round funding?
- In February 2016, Regentis Biomaterials raised $15,000,000 in its D Round funding, with lead investors including Haisco.
- When did Regentis Biomaterials announce the closing of its Initial Public Offering?
- Regentis Biomaterials Ltd. announced the closing of its Initial Public Offering in December 2025.
- Who was appointed as Chief Medical Officer for Regentis Biomaterials in February 2026?
- In February 2026, Regentis Biomaterials appointed Dr. Galit Reske as its Chief Medical Officer.
- What is the current employee count for Regentis Biomaterials?
- Regentis Biomaterials has 1-10 employees.
- What was the amount of Regentis Biomaterials' public offering in December 2025?
- Regentis Biomaterials had a public offering of $10,000,000 in December 2025.
- What is the latest patent granted to Regentis Biomaterials?
- In December 2025, Regentis Biomaterials was granted a new U.S. patent for its off-the-shelf regenerative cartilage repair product, GelrinC.
Team · 10
Dr. Dror Seliktar
Founder · Co-Founder and Chief Scientific Officer
Dr. Ehud Geller
Chief Executive Officer and Executive Chairman
Ori Gon
Chief Financial Officer and Chief Business Officer
Arie Gordashnikov
Chief Accounting Officer
Dr. Galit Reske
Chief Medical Officer
Jeff Dykan
Director
Susan Alpert, PhD
Independent Director
Pini Ben-Elazar
Independent Director
Keith C. Valentine
Independent Director
Efraim Cohen-Arazi
Independent Director
Sectors & technology
Primary sector
Health Tech & Life Sciences
Technologies
Tags
biomaterialsmedical-devicesorthopedicsmedical-technologiestissue-regenerationregenerative-medicinesurgerybiodegradablepain-reliefdrug-deliverynanotechnology
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | regentis.co.il |
|---|---|
| linkedin.com/company/6144951 | |
| YouTube | youtube.com/channel/UCY231jR34KUS6RMeh6GbA0g |
| Wikidata | wikidata.org/wiki/Q30260681 |
Identifiers & details
| Legal name | Regentis Biomaterials Ltd. |
|---|---|
| Founded | 2004-9 |
| Employees (exact) | 8 |
| Offices | Princeton; Mnster |
| Market cap | $34.9M |
| Status reason | Public on NASDAQ on Sep, 2025; |
| Wikidata QID | Q30260681 |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| IPO | 2025-12 | NYSE American | RGNT | $10.0M |
Radar intelligence
Patents
| EPO | 10 |
|---|
Web history (Wayback)
| Domain | regentis.co.il |
|---|
Wikidata
| QID | Q30260681 |
|---|
Certificate / subdomain footprint
| Subdomains | 4 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 513585240 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2004-09-01 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | yes |
| Last annual report | 2023 |
| Active charges / liens | 0 |
| Registry events | 1 — violation (1) |
| Registered address | מדינת היהודים 60 הרצליה |
Recent registry events
| Date | Event |
|---|---|
| 2026-06-25 | עדכון הפרה |